Image courtesy of Shutterstock
Obesity, insulin resistance, type 2 diabetes (T2D) and associated cardiovascular disease (CVD) – all metabolic diseases – are an epidemic global health problem.
With almost 400 million people worldwide suffering from T2D and total deaths from the condition due to rise by more than 50% in the next 10 years, research which addresses the causes of these diseases and delivers effective treatment for them is of paramount importance. So two Oxford teams are beginning research programmes, funded by the Novo Nordisk Foundation.